Treatment of chronic proliferative cholangitis with c-myc shRNA

World Journal of Gastroenterology

Volumn 15, Issue 1, 2009, Pages 95-101

  Li, Fu Yu ^a   Cheng, Nan Sheng ^a   Cheng, Jing Qiu ^a   Mao, Hui ^a   Jiang, Li Sheng ^a   Li, Ning ^a   He, Sheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

C myc; Chronic proliferative cholangitis; Hepatolithiasis; Prevention; Recurrence

Indexed keywords

BETA GLUCURONIDASE; COLLAGEN FIBER; CYCLINE; HYDROXYPROLINE; MUCIN 5AC; MYC PROTEIN; PROCOLLAGEN; PROCOLLAGEN 3; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT OBSTRUCTION; BILE DUCT STONE; BIOCHEMISTRY; CHOLANGITIS; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; ENZYME HISTOCHEMISTRY; ENZYME RELEASE; EPITHELIUM HYPERPLASIA; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; RISK REDUCTION; RNA INTERFERENCE; STONE FORMATION; WESTERN BLOTTING;

EID: 59249095924     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.95     Document Type: Article

References (35)

1. Li SQ, Liang LJ, Peng BG, Lai JM, Lu MD, Li DM. Hepaticojejunostomy for hepatolithiasis: a critical appraisal. World J Gastroenterol 2006; 12: 4170-4174
2. Chijiiwa K, Yamashita H, Yoshida J, Kuroki S, Tanaka M. Current management and long-term prognosis of hepatolithiasis. Arch Surg 1995; 130: 194-197
3. Chen DW, Tung-Ping Poon R, Liu CL, Fan ST, Wong J. Immediate and long-term outcomes of hepatectomy for hepatolithiasis. Surgery 2004; 135: 386-393
4. Kim BW, Wang HJ, Kim WH, Kim MW. Favorable outcomes of hilar duct oriented hepatic resection for high grade Tsunoda type hepatolithiasis. World J Gastroenterol 2006; 12: 431-436
5. Hwang JH, Yoon YB, Kim YT, Cheon JH, Jeong JB. Risk factors for recurrent cholangitis after initial hepatolithiasis treatment. J Clin Gastroenterol 2004; 38: 364-367
6. Buscaino GA, Striano S. [Neurochemistry of convulsiveness. Some neurobiological mechanisms of experimental and human epilepsy] Acta Neurol (Napoli) 1976; 31: 413-423
7. Freitas ML, Bell RL, Duffy AJ. Choledocholithiasis: evolving standards for diagnosis and management. World J Gastroenterol 2006; 12: 3162-3167
8. Fujii H, Yang Y, Matsumoto Y, Suda K. Current problems with intrahepatic bile duct stones in Japan - congenital biliary malformations as a cause. Hepatogastroenterology 1997; 44: 328-341
9. Geng ZM, Yao YM, Liu QG, Niu XJ, Liu XG. Mechanism of benign biliary stricture: a morphological and immunohistochemical study. World J Gastroenterol 2005; 11: 293-295
10. De Palma GD, Masone S, Rega M, Simeoli I, Salvatori F, Siciliano S, Maione F, Girardi V, Celiento M, Persico G. Endoscopic approach to malignant strictures at the hepatic hilum. World J Gastroenterol 2007; 13: 4042-4045
11. Terada T, Nakanuma Y. Pathologic observations of intrahepatic peribiliary glands in 1,000 consecutive autopsy livers: IV. Hyperplasia of intramural and extramural glands. Hum Pathol 1992; 23: 483-490
12. Li FY, Cheng JQ, Li N, He S, Zhang MM, Dong JH, Jiang LS, Cheng NS. Effectiveness of chemical biliary duct embolization for chemical hepatectomy. J Gastroenterol Hepatol 2006; 21: 880-886
13. Li F, Cheng J, He S, Li N, Zhang M, Dong J, Jiang L, Cheng N, Xiong X. The practical value of applying chemical biliary duct embolization to chemical hepatectomy for treatment of hepatolithiasis. J Surg Res 2005; 127: 131-138
14. Li FY, Cheng JQ, Mao H, Li N, Jiang LS, Cheng NS, Wu XW. Treatment of hepatolithiasis by endoscopic chemoembolization of the left hepatic duct. Endoscopy 2006; 38: 845-847
15. Terada T, Nakanuma Y. Innervation of intrahepatic bile ducts and peribiliary glands in normal human livers, extrahepatic biliary obstruction and hepatolithiasis. An immunohistochemical study. J Hepatol 1989; 9: 141-148
16. Lu S, Yan L, Rao L, Xia T, Gou J, Zhang S, Lei S. Down stream involvement of the bile duct in hepatolithiasis. Chin Med J (Engl) 2002; 115: 62-64
17. Nakanuma Y, Yamaguchi K, Ohta G, Terada T. Pathologic features of hepatolithiasis in Japan. Hum Pathol 1988; 19: 1181-1186
18. Ehsan A, Mann MJ. Antisense and gene therapy to prevent restenosis. Vasc Med 2000; 5: 103-114
19. Yamamoto K. Intrahepatic periductal glands and their significance in primary intrahepatic lithiasis. Jpn J Surg 1982; 12: 163-170
20. Park SM, Choi JW, Kim ST, Cho MC, Sung RH, Jang LC, Park JW, Lee SP, Park YH. Suppression of proliferative cholangitis in a rat model by local delivery of paclitaxel. J Hepatobiliary Pancreat Surg 2003; 10: 176-182
21. Ballantyne B, Wood WG. Biochemical and histochemical observations on Beta-glucuronidase in the mammalian gallbladder. Am J Dig Dis 1968; 13: 551-557
22. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981; 112: 70-75
23. Weber A, Huber W, Kamereck K, Winkle P, Voland P, Weidenbach H, Schmid RM, Prinz C. In vitro activity of moxifloxacin and piperacillin/ sulbactam against pathogens of acute cholangitis. World J Gastroenterol 2008; 14: 3174-3178
24. Yang HM, Wu J, Li JY, Gu L, Zhou MF. Role of nucleation of bile liquid crystal in gallstone formation. World J Gastroenterol 2003; 9: 1791-1794
25. Yamasaki T, Nakayama F, Tamura S, Endo M. Characterization of mucin in the hepatic bile of patients with intrahepatic pigment stones. J Gastroenterol Hepatol 1992; 7: 36-41
26. Li N, Xiao LJ, Chen SW, Li L, Xiao BL, Chen WB, Gao XK, Gu SJ. [Mucus histochemical study of bilirubin cholangiolithiasis in rabbit model] Huaxi Yike Daxue Xuebao 1989; 20: 417-420
27. Hoffman B, Liebermann DA, Selvakumaran M, Nguyen HQ. Role of c-myc in myeloid differentiation, growth arrest and apoptosis. Curr Top Microbiol Immunol 1996; 211: 17-27
28. Biro S, Fu YM, Yu ZX, Epstein SE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA 1993; 90: 654-658
29. Ehsan A, Mann MJ. Antisense and gene therapy to prevent restenosis. Vasc Med 2000; 5: 103-114
30. Edelman ER, Simons M, Sirois MG, Rosenberg RD. c-myc in vasculoproliferative disease. Circ Res 1995; 76: 176-182
31. Zen Y, Harada K, Sasaki M, Tsuneyama K, Katayanagi K, Yamamoto Y, Nakanuma Y. Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells: possible key phenomenon of hepatolithiasis. Am J Pathol 2002; 161: 1475-1484
32. Lee KT, Liu TS. Altered mucin gene expression in stone-containing intrahepatic bile ducts and cholangiocarcinomas. Dig Dis Sci 2001; 46: 2166-2172
33. Chen CY, Shiesh SC, Tsao HC, Lin XZ. Human biliary beta-glucuronidase activity before and after relief of bile duct obstruction: is it the major role in the formation of pigment gallstones? J Gastroenterol Hepatol 2000; 15: 1071-1075
34. Mitra AK, Agrawal DK. Gene therapy of fibroproliferative vasculopathies: current ideas in molecular mechanisms and biomedical technology. Pharmacogenomics 2006; 7: 1185-1198
35. Bennett MR, Schwartz SM. Antisense therapy for angioplasty restenosis. Some critical considerations. Circulation 1995; 92: 1981-1993